Probing Dry-Weight Improves Left Ventricular Mass Index

Background: Although probing dry-weight improves blood pressure control, its effect on echocardiographic left ventricular mass index (LVMI) is unknown. Methods: Shortly following dialysis, 292 echocardiograms in 150 patients participating in the DRIP trial were obtained at baseline and longitudinally every 4 weeks on 2 occasions. Results: At baseline, LVMI was 136.3 g/m2 in the control group and 138.7 g/m2 in the ultrafiltration group (p > 0.2 for difference). The change from baseline in LVMI in the control group was +3.5 g/m2 at 4 weeks and +0.3 g/m2 at 8 weeks (p > 0.2 for both changes). The change from baseline in LVMI in the ultrafiltration group was –7.4 g/m2 at 4 weeks (p = 0.005) and –6.3 g/m2 at 8 weeks (p = 0.045). With ultrafiltration, the change in LVMI diameter was –10.9 g/m2 more compared to the control group at 4 weeks (p = 0.012) and –6.6 g/m2 more compared to the control group at 8 weeks (p = 0.21). The reduction in interdialytic ambulatory blood pressure was also greater in response to probing dry-weight in those in the top half of LVMI at baseline (p = 0.02 for interaction effect at week 8). Conclusion: LVMI, an important determinant of prognosis among long-term dialysis patients, is responsive to probing dry-weight.

[1]  G. Beck,et al.  In-center hemodialysis six times per week versus three times per week. , 2010, The New England journal of medicine.

[2]  R. Agarwal,et al.  Dry-Weight Reduction in Hypertensive Hemodialysis Patients (DRIP): A Randomized, Controlled Trial , 2009, Hypertension.

[3]  O. Ozdogan,et al.  The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  R. Light,et al.  Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  N. Bodyak,et al.  Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals , 2007, Proceedings of the National Academy of Sciences.

[6]  C. Saha,et al.  Out-of-Hemodialysis-Unit Blood Pressure Is a Superior Determinant of Left Ventricular Hypertrophy , 2006, Hypertension.

[7]  Jeffrey C. Hill,et al.  Analysis of left ventricular systolic function using midwall mechanics in patients >60 years of age with hypertensive heart disease and heart failure. , 2005, The American journal of cardiology.

[8]  J. Singer,et al.  Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  A. Go,et al.  Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. , 2005, Journal of the American Society of Nephrology : JASN.

[10]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[11]  David Voss,et al.  Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  E. Ok,et al.  Impact of volume control on left ventricular hypertrophy in dialysis patients. , 2002, Journal of nephrology.

[13]  C. Specchia,et al.  Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  Christopher T. Chan,et al.  Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. , 2002, Kidney international.

[15]  J. Blacher,et al.  Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. , 2001, Journal of the American Society of Nephrology : JASN.

[16]  C. Zoccali,et al.  Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. , 2001, Journal of the American Society of Nephrology : JASN.

[17]  J. Singer,et al.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  C. Park,et al.  Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  F. Akçiçek,et al.  Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  D. Rolla,et al.  Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  J. Singer,et al.  Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  G. Aurigemma,et al.  Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. , 1995, Journal of the American College of Cardiology.

[23]  E. Paoletti,et al.  Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. , 1993, Kidney international.

[24]  W. Kannel Left ventricular hypertrophy as a risk factor: the Framingham experience , 1991, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[25]  E. Movilli,et al.  Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  D E Manyari,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[27]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.